See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer regarding the safety of receiving inactive vaccines while on Cosentyx (secukinumab) therapy. Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting a specific protein in the body (interleukin-17A) to reduce inflammation [1].

Inactive vaccines, also known as killed or non-live vaccines, contain whole or partial pieces of a virus or bacteria that have been killed or inactivated, making them unable to replicate and cause disease [2]. Examples of inactive vaccines include those for hepatitis A, influenza (inactivated), and rabies [2].

According to the Cosentyx prescribing information, there are limited data on the use of Cosentyx in patients receiving vaccinations [1]. The manufacturer recommends that live vaccines should be avoided in patients treated with Cosentyx, as there is a risk of infection with live vaccines [1]. However, the safety of inactive vaccines during Cosentyx therapy has not been specifically addressed in the prescribing information [1].

DrugPatentWatch.com, a website that tracks drug patents and pharmaceutical market strategies, does not provide information on the safety of vaccinations during Cosentyx therapy [3].

In summary, while there is no specific information suggesting that inactive vaccines are unsafe during Cosentyx therapy, live vaccines should be avoided [1]. Patients should consult their healthcare provider for personalized advice regarding vaccinations while on Cosentyx therapy.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Accessed on March 23, 2023, from: https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf
2. Centers for Disease Control and Prevention. Types of vaccines. Accessed on March 23, 2023, from: https://www.cdc.gov/vaccines/vac-gen/types.htm
3. DrugPatentWatch.com. Secukinumab. Accessed on March 23, 2023, from: https://www.drugpatentwatch.com/drugs/secukinumab